60 Degrees Pharmaceuticals Inc SXTP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
-
60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
-
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
-
60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
-
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
-
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
-
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
Trading Information
- Previous Close Price
- $0.90
- Day Range
- $0.85–0.91
- 52-Week Range
- $0.84–8.62
- Bid/Ask
- $0.80 / $0.91
- Shares Outstanding
- 3.52M
- Market Cap
- $3.01M
- Volume/Avg
- 13,550 / 128,283
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.23
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
- Website
- https://www.60degreespharma.com
Valuation
|
Metric
|
SXTP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1.23 |
Price/Cash Flow | — |
Price/Earnings
SXTP
Financial Strength
|
Metric
|
SXTP
|
|---|---|
Quick Ratio | 0.99 |
Current Ratio | 2.32 |
Interest Coverage | −1,068.52 |
Quick Ratio
SXTP
Profitability
|
Metric
|
SXTP
|
|---|---|
Return on Assets (Normalized) | −148.39% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −223.36% |
Return on Assets
SXTP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>!k&Nl | LOCK|Gs&My | $127B | |||
| Moderna Inc
MRNA
| LOCK|ZFRn<L | LOCK|@^ | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|h#$!&N | LOCK|j%x<z | $81B | |||
| argenx SE ADR
ARGX
| LOCK|V^B<@$c | LOCK|t<H | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|KXtM>!@ | LOCK|<t | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$?JcYMQ | LOCK|GRK&Q | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>nV?&c&< | LOCK|YFM? | $27B | |||
| Incyte Corp
INCY
| LOCK|>Dbd>z# | LOCK|<Wl | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|r>?<Qz | LOCK|tPB | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|?%&&@B | LOCK|<>y | $14B |
United States